QQQ   323.59 (+3.01%)
AAPL   127.79 (+5.39%)
MSFT   236.94 (+1.96%)
FB   264.91 (+2.83%)
GOOGL   2,069.66 (+2.36%)
TSLA   718.43 (+6.36%)
AMZN   3,146.14 (+1.72%)
NVDA   553.67 (+0.93%)
BABA   241.69 (+1.65%)
CGC   34.73 (+6.05%)
GE   13.11 (+4.55%)
MU   94.76 (+3.53%)
NIO   49.76 (+8.69%)
AMD   86.39 (+2.22%)
T   28.09 (+0.72%)
F   11.98 (+2.39%)
ACB   11.04 (+4.94%)
DIS   194.98 (+3.14%)
BA   224.39 (+5.84%)
NFLX   550.64 (+2.19%)
BAC   35.79 (+3.11%)
QQQ   323.59 (+3.01%)
AAPL   127.79 (+5.39%)
MSFT   236.94 (+1.96%)
FB   264.91 (+2.83%)
GOOGL   2,069.66 (+2.36%)
TSLA   718.43 (+6.36%)
AMZN   3,146.14 (+1.72%)
NVDA   553.67 (+0.93%)
BABA   241.69 (+1.65%)
CGC   34.73 (+6.05%)
GE   13.11 (+4.55%)
MU   94.76 (+3.53%)
NIO   49.76 (+8.69%)
AMD   86.39 (+2.22%)
T   28.09 (+0.72%)
F   11.98 (+2.39%)
ACB   11.04 (+4.94%)
DIS   194.98 (+3.14%)
BA   224.39 (+5.84%)
NFLX   550.64 (+2.19%)
BAC   35.79 (+3.11%)
QQQ   323.59 (+3.01%)
AAPL   127.79 (+5.39%)
MSFT   236.94 (+1.96%)
FB   264.91 (+2.83%)
GOOGL   2,069.66 (+2.36%)
TSLA   718.43 (+6.36%)
AMZN   3,146.14 (+1.72%)
NVDA   553.67 (+0.93%)
BABA   241.69 (+1.65%)
CGC   34.73 (+6.05%)
GE   13.11 (+4.55%)
MU   94.76 (+3.53%)
NIO   49.76 (+8.69%)
AMD   86.39 (+2.22%)
T   28.09 (+0.72%)
F   11.98 (+2.39%)
ACB   11.04 (+4.94%)
DIS   194.98 (+3.14%)
BA   224.39 (+5.84%)
NFLX   550.64 (+2.19%)
BAC   35.79 (+3.11%)
QQQ   323.59 (+3.01%)
AAPL   127.79 (+5.39%)
MSFT   236.94 (+1.96%)
FB   264.91 (+2.83%)
GOOGL   2,069.66 (+2.36%)
TSLA   718.43 (+6.36%)
AMZN   3,146.14 (+1.72%)
NVDA   553.67 (+0.93%)
BABA   241.69 (+1.65%)
CGC   34.73 (+6.05%)
GE   13.11 (+4.55%)
MU   94.76 (+3.53%)
NIO   49.76 (+8.69%)
AMD   86.39 (+2.22%)
T   28.09 (+0.72%)
F   11.98 (+2.39%)
ACB   11.04 (+4.94%)
DIS   194.98 (+3.14%)
BA   224.39 (+5.84%)
NFLX   550.64 (+2.19%)
BAC   35.79 (+3.11%)
Log in
NASDAQ:CUR

Neuralstem Competitors

Notice: This company has been marked as potentially delisted and may not be actively trading.
$1.45
+0.11 (+8.21 %)
(As of 03/1/2021 12:00 AM ET)
Add
Compare
Today's Range
$1.36
Now: $1.45
$1.50
50-Day Range
$0.67
MA: $1.06
$1.52
52-Week Range
$1.10
Now: $1.45
$13.78
Volume627,380 shs
Average Volume236,278 shs
Market Capitalization$3.05 million
P/E RatioN/A
Dividend YieldN/A
Beta1.81

Competitors

Neuralstem (NASDAQ:CUR) Vs. AMGN, GILD, MRNA, BIIB, SGEN, and BNTX

Should you be buying CUR stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to Neuralstem, including Amgen (AMGN), Gilead Sciences (GILD), Moderna (MRNA), Biogen (BIIB), Seagen (SGEN), and BioNTech (BNTX).

Amgen (NASDAQ:AMGN) and Neuralstem (NASDAQ:CUR) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, valuation, risk and analyst recommendations.

Earnings & Valuation

This table compares Amgen and Neuralstem's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amgen$23.36 billion5.61$7.84 billion$14.8215.32
Neuralstem$260,000.0011.71$-4,930,000.00N/AN/A

Amgen has higher revenue and earnings than Neuralstem.

Profitability

This table compares Amgen and Neuralstem's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Amgen29.42%95.55%15.52%
Neuralstem-39,417.64%-170.51%-110.16%

Volatility & Risk

Amgen has a beta of 0.76, indicating that its stock price is 24% less volatile than the S&P 500. Comparatively, Neuralstem has a beta of 1.81, indicating that its stock price is 81% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings for Amgen and Neuralstem, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Amgen0111402.56
Neuralstem0000N/A

Amgen presently has a consensus price target of $256.4091, indicating a potential upside of 12.94%. Given Amgen's higher probable upside, research analysts clearly believe Amgen is more favorable than Neuralstem.

Insider & Institutional Ownership

75.2% of Amgen shares are owned by institutional investors. Comparatively, 38.3% of Neuralstem shares are owned by institutional investors. 0.4% of Amgen shares are owned by insiders. Comparatively, 5.4% of Neuralstem shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Amgen beats Neuralstem on 8 of the 11 factors compared between the two stocks.

Gilead Sciences (NASDAQ:GILD) and Neuralstem (NASDAQ:CUR) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, valuation, risk and analyst recommendations.

Earnings & Valuation

This table compares Gilead Sciences and Neuralstem's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gilead Sciences$22.45 billion3.49$5.39 billion$6.1410.17
Neuralstem$260,000.0011.71$-4,930,000.00N/AN/A

Gilead Sciences has higher revenue and earnings than Neuralstem.

Profitability

This table compares Gilead Sciences and Neuralstem's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Gilead Sciences5.48%37.77%12.76%
Neuralstem-39,417.64%-170.51%-110.16%

Volatility & Risk

Gilead Sciences has a beta of 0.51, indicating that its stock price is 49% less volatile than the S&P 500. Comparatively, Neuralstem has a beta of 1.81, indicating that its stock price is 81% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings for Gilead Sciences and Neuralstem, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Gilead Sciences1121202.44
Neuralstem0000N/A

Gilead Sciences presently has a consensus price target of $96.0370, indicating a potential upside of 53.76%. Given Gilead Sciences' higher probable upside, research analysts clearly believe Gilead Sciences is more favorable than Neuralstem.

Insider & Institutional Ownership

76.4% of Gilead Sciences shares are owned by institutional investors. Comparatively, 38.3% of Neuralstem shares are owned by institutional investors. 0.1% of Gilead Sciences shares are owned by insiders. Comparatively, 5.4% of Neuralstem shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Gilead Sciences beats Neuralstem on 8 of the 11 factors compared between the two stocks.

Moderna (NASDAQ:MRNA) and Neuralstem (NASDAQ:CUR) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, valuation, risk and analyst recommendations.

Earnings & Valuation

This table compares Moderna and Neuralstem's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Moderna$60.21 million1,034.46$-514,020,000.00($1.55)-101.55
Neuralstem$260,000.0011.71$-4,930,000.00N/AN/A

Neuralstem has lower revenue, but higher earnings than Moderna.

Profitability

This table compares Moderna and Neuralstem's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Moderna-242.73%-28.11%-20.31%
Neuralstem-39,417.64%-170.51%-110.16%

Volatility & Risk

Moderna has a beta of 1.73, indicating that its stock price is 73% more volatile than the S&P 500. Comparatively, Neuralstem has a beta of 1.81, indicating that its stock price is 81% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings for Moderna and Neuralstem, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Moderna36902.33
Neuralstem0000N/A

Moderna presently has a consensus price target of $149.6471, indicating a potential downside of 4.93%. Given Moderna's higher probable upside, research analysts clearly believe Moderna is more favorable than Neuralstem.

Insider & Institutional Ownership

51.2% of Moderna shares are owned by institutional investors. Comparatively, 38.3% of Neuralstem shares are owned by institutional investors. 29.2% of Moderna shares are owned by insiders. Comparatively, 5.4% of Neuralstem shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Moderna beats Neuralstem on 9 of the 11 factors compared between the two stocks.

Biogen (NASDAQ:BIIB) and Neuralstem (NASDAQ:CUR) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, valuation, risk and analyst recommendations.

Profitability

This table compares Biogen and Neuralstem's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Biogen35.63%51.00%23.54%
Neuralstem-39,417.64%-170.51%-110.16%

Analyst Ratings

This is a summary of recent ratings for Biogen and Neuralstem, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Biogen5151202.22
Neuralstem0000N/A

Biogen presently has a consensus price target of $304.4667, indicating a potential upside of 11.43%. Given Biogen's higher probable upside, research analysts clearly believe Biogen is more favorable than Neuralstem.

Insider & Institutional Ownership

83.5% of Biogen shares are owned by institutional investors. Comparatively, 38.3% of Neuralstem shares are owned by institutional investors. 0.5% of Biogen shares are owned by insiders. Comparatively, 5.4% of Neuralstem shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Biogen and Neuralstem's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biogen$14.38 billion2.90$5.89 billion$33.578.14
Neuralstem$260,000.0011.71$-4,930,000.00N/AN/A

Biogen has higher revenue and earnings than Neuralstem.

Volatility & Risk

Biogen has a beta of 0.53, indicating that its stock price is 47% less volatile than the S&P 500. Comparatively, Neuralstem has a beta of 1.81, indicating that its stock price is 81% more volatile than the S&P 500.

Summary

Biogen beats Neuralstem on 8 of the 11 factors compared between the two stocks.

Neuralstem (NASDAQ:CUR) and Seagen (NASDAQ:SGEN) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.

Profitability

This table compares Neuralstem and Seagen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Neuralstem-39,417.64%-170.51%-110.16%
Seagen25.34%20.46%16.67%

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Neuralstem and Seagen, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Neuralstem0000N/A
Seagen151112.67

Seagen has a consensus price target of $188.4615, indicating a potential upside of 23.54%. Given Seagen's higher probable upside, analysts plainly believe Seagen is more favorable than Neuralstem.

Insider and Institutional Ownership

38.3% of Neuralstem shares are owned by institutional investors. Comparatively, 87.2% of Seagen shares are owned by institutional investors. 5.4% of Neuralstem shares are owned by insiders. Comparatively, 31.1% of Seagen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Neuralstem and Seagen's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Neuralstem$260,000.0011.71$-4,930,000.00N/AN/A
Seagen$916.71 million30.15$-158,650,000.00($1.33)-114.70

Neuralstem has higher earnings, but lower revenue than Seagen.

Risk and Volatility

Neuralstem has a beta of 1.81, indicating that its share price is 81% more volatile than the S&P 500. Comparatively, Seagen has a beta of 1.11, indicating that its share price is 11% more volatile than the S&P 500.

Summary

Seagen beats Neuralstem on 10 of the 12 factors compared between the two stocks.

Neuralstem (NASDAQ:CUR) and BioNTech (NASDAQ:BNTX) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.

Profitability

This table compares Neuralstem and BioNTech's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Neuralstem-39,417.64%-170.51%-110.16%
BioNTech-250.12%-66.72%-41.73%

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Neuralstem and BioNTech, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Neuralstem0000N/A
BioNTech04302.43

BioNTech has a consensus price target of $102.75, indicating a potential downside of 6.77%. Given BioNTech's higher probable upside, analysts plainly believe BioNTech is more favorable than Neuralstem.

Insider and Institutional Ownership

38.3% of Neuralstem shares are owned by institutional investors. Comparatively, 10.8% of BioNTech shares are owned by institutional investors. 5.4% of Neuralstem shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Neuralstem and BioNTech's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Neuralstem$260,000.0011.71$-4,930,000.00N/AN/A
BioNTech$121.63 million218.18$-200,540,000.00($0.95)-116.01

Neuralstem has higher earnings, but lower revenue than BioNTech.

Risk and Volatility

Neuralstem has a beta of 1.81, indicating that its share price is 81% more volatile than the S&P 500. Comparatively, BioNTech has a beta of -1.74, indicating that its share price is 274% less volatile than the S&P 500.

Summary

BioNTech beats Neuralstem on 7 of the 11 factors compared between the two stocks.


Neuralstem Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Amgen logo
AMGN
Amgen
2.5$227.04+0.9%$131.13 billion$23.36 billion18.31Analyst Report
Gilead Sciences logo
GILD
Gilead Sciences
2.8$62.46+1.7%$78.30 billion$22.45 billion64.39
Moderna logo
MRNA
Moderna
1.6$157.40+1.6%$62.28 billion$60.21 million-97.16Earnings Announcement
Analyst Report
Insider Selling
Decrease in Short Interest
Analyst Revision
Biogen logo
BIIB
Biogen
1.9$273.24+0.1%$41.62 billion$14.38 billion9.04
Seagen logo
SGEN
Seagen
1.5$152.55+0.9%$27.64 billion$916.71 million60.06Decrease in Short Interest
BioNTech logo
BNTX
BioNTech
0.9$110.21+1.1%$26.54 billion$121.63 million-55.11Decrease in Short Interest
argenx logo
ARGX
argenx
1.1$340.53+2.9%$16.12 billion$78.17 million-71.99Upcoming Earnings
Novavax logo
NVAX
Novavax
1.2$240.29+3.8%$15.30 billion$18.66 million-46.03Earnings Announcement
Gap Down
Bio-Techne logo
TECH
Bio-Techne
1.8$372.44+2.9%$14.45 billion$738.69 million59.59Analyst Upgrade
Gap Down
Repligen logo
RGEN
Repligen
1.5$221.73+4.2%$12.14 billion$270.24 million270.40Earnings Announcement
Analyst Revision
QIAGEN logo
QGEN
QIAGEN
1.7$50.36+0.7%$11.47 billion$1.53 billion62.17
Neurocrine Biosciences logo
NBIX
Neurocrine Biosciences
2.1$109.43+0.1%$10.28 billion$788.10 million117.67Analyst Revision
CRISPR Therapeutics logo
CRSP
CRISPR Therapeutics
1.5$130.25+3.5%$9.82 billion$289.59 million-39.95Analyst Report
Fate Therapeutics logo
FATE
Fate Therapeutics
1.6$96.61+7.1%$9.06 billion$10.68 million-52.51Earnings Announcement
Analyst Report
Analyst Revision
Gap Down
Vir Biotechnology logo
VIR
Vir Biotechnology
0.8$66.73+6.1%$8.50 billion$8.09 million-28.28Earnings Announcement
Acceleron Pharma logo
XLRN
Acceleron Pharma
1.4$140.15+2.8%$8.44 billion$73.99 million-54.11Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Adaptive Biotechnologies logo
ADPT
Adaptive Biotechnologies
1.2$57.89+2.3%$8.06 billion$85.07 million-60.94Earnings Announcement
Analyst Report
Insider Selling
Denali Therapeutics logo
DNLI
Denali Therapeutics
1.1$64.66+11.0%$7.75 billion$26.68 million-29.26Earnings Announcement
Analyst Report
Twist Bioscience logo
TWST
Twist Bioscience
1.2$144.95+5.0%$7.05 billion$90.10 million-38.65Gap Down
Halozyme Therapeutics logo
HALO
Halozyme Therapeutics
1.5$46.47+2.6%$6.29 billion$195.99 million290.44Earnings Announcement
Insider Selling
Analyst Revision
Kodiak Sciences logo
KOD
Kodiak Sciences
1.3$134.79+4.3%$6.04 billionN/A-58.10Analyst Downgrade
News Coverage
Gap Up
Iovance Biotherapeutics logo
IOVA
Iovance Biotherapeutics
1.7$39.47+5.5%$5.79 billionN/A-20.56Earnings Announcement
Analyst Revision
News Coverage
Gap Down
Beam Therapeutics logo
BEAM
Beam Therapeutics
0.9$95.58+6.7%$5.54 billion$20,000.00-6.80Analyst Downgrade
Analyst Revision
Gap Down
Allogene Therapeutics logo
ALLO
Allogene Therapeutics
1.3$36.50+4.9%$5.12 billionN/A-17.14Earnings Announcement
Analyst Report
Analyst Revision
Gap Down
China Biologic Products logo
CBPO
China Biologic Products
0.8$118.20+1.1%$4.65 billion$503.70 million33.02Increase in Short Interest
News Coverage
SpringWorks Therapeutics logo
SWTX
SpringWorks Therapeutics
1.4$86.95+1.0%$4.24 billionN/A-49.97Earnings Announcement
Analyst Report
Gap Down
NantKwest logo
NK
NantKwest
1.1$33.30+2.4%$3.63 billion$40,000.00-46.90Decrease in Short Interest
Gap Down
RLAY
Relay Therapeutics
1.8$40.19+2.7%$3.62 billionN/A0.00Gap Down
NanoString Technologies logo
NSTG
NanoString Technologies
1.3$74.36+6.1%$3.28 billion$125.57 million-43.49News Coverage
Gap Down
Revolution Medicines logo
RVMD
Revolution Medicines
1.3$45.99+0.7%$3.05 billion$50.04 million0.00Upcoming Earnings
Editas Medicine logo
EDIT
Editas Medicine
1.2$46.89+6.5%$2.94 billion$20.53 million-26.95Earnings Announcement
Analyst Downgrade
Analyst Revision
News Coverage
Sorrento Therapeutics logo
SRNE
Sorrento Therapeutics
1.3$10.25+5.7%$2.87 billion$31.43 million-7.02Gap Down
AlloVir logo
ALVR
AlloVir
1.4$38.38+4.7%$2.50 billionN/A0.00Gap Down
Vericel logo
VCEL
Vericel
1.3$48.17+0.2%$2.21 billion$117.85 million-4,817,000.00Earnings Announcement
Analyst Downgrade
Analyst Revision
Gap Down
Kymera Therapeutics logo
KYMR
Kymera Therapeutics
0.8$48.46+1.0%$2.15 billionN/A0.00Upcoming Earnings
High Trading Volume
News Coverage
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.1$11.98+10.0%$2.12 billion$48.83 million-15.76Earnings Announcement
Analyst Report
Analyst Revision
Gap Down
bluebird bio logo
BLUE
bluebird bio
1.8$30.08+3.4%$2.00 billion$44.67 million-2.74Earnings Announcement
Analyst Revision
Scholar Rock logo
SRRK
Scholar Rock
1.1$56.80+4.8%$1.91 billion$20.49 million-23.57Gap Down
Ocugen logo
OCGN
Ocugen
1.1$10.02+9.3%$1.88 billionN/A-6.77Decrease in Short Interest
Gap Up
C4 Therapeutics logo
CCCC
C4 Therapeutics
1.1$42.39+1.3%$1.82 billionN/A0.00Upcoming Earnings
Translate Bio logo
TBIO
Translate Bio
1.4$23.80+1.9%$1.77 billion$7.80 million-22.24Analyst Report
Gap Down
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$11.99+4.2%$1.72 billion$102.43 million-19.98Earnings Announcement
Analyst Revision
News Coverage
Gap Down
Krystal Biotech logo
KRYS
Krystal Biotech
1.3$85.46+7.7%$1.68 billionN/A-57.74Analyst Report
News Coverage
Gap Down
Replimune Group logo
REPL
Replimune Group
1.5$35.42+2.2%$1.65 billionN/A-20.01Gap Down
REGENXBIO logo
RGNX
REGENXBIO
1.8$42.51+3.8%$1.59 billion$35.23 million-17.14Gap Down
FMTX
Forma Therapeutics
1.8$38.49+0.3%$1.58 billion$100.56 million0.00Upcoming Earnings
Decrease in Short Interest
Immunovant logo
IMVT
Immunovant
1.8$14.85+6.3%$1.45 billionN/A-11.51High Trading Volume
Increase in Short Interest
Gap Down
Alector logo
ALEC
Alector
1.3$17.43+4.3%$1.38 billion$21.22 million-7.82Earnings Announcement
Atara Biotherapeutics logo
ATRA
Atara Biotherapeutics
1.4$17.11+1.9%$1.33 billionN/A-3.70News Coverage
Gap Down
PCVX
Vaxcyte
1.8$25.83+8.8%$1.32 billionN/A0.00Upcoming Earnings
This page was last updated on 3/1/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.